NS-102 |
| Katalog-Nr.GC64133 |
NS-102 ist ein selektiver Kainat (GluK2)-Rezeptorantagonist.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 136623-01-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
NS-102 is a selective kainate (GluK2) receptor antagonist. NS-102 is a potent GluR6/7 receptor antagonist[1][2][3].
Combination of NS-102 (10 μM) and GYKI 52466 (30 μM) preventes full loss of compound action potentials (CAPs) during oxygen and glucose deprivation (OGD) and increases CAP area recovery[1].
NS-102 (20, 40 or 80 μmol/litre ; in the hippocampal CA3 region) significantly reduces Sevoflurane-induced hyperactivities[1].
[1]. Selva Baltan TekkÖk, et al. Excitotoxic mechanisms of ischemic injury in myelinated white matter. J Cereb Blood Flow Metab. 2007 Sep;27(9):1540-52.
[2]. P Liang, et al. Sevoflurane activates hippocampal CA3 kainate receptors (Gluk2) to induce hyperactivity during induction and recovery in a mouse model. Br J Anaesth. 2017 Nov 1;119(5):1047-1054.
[3]. Barbara Gisabella, et al. Kainate receptor-mediated modulation of hippocampal fast spiking interneurons in a rat model of schizophrenia. PLoS One. 2012;7(3):e32483.
Average Rating: 5 (Based on Reviews and 1 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *